Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
1,033.23
+1.57 (+0.15%)
Streaming Delayed Price
Updated: 9:39 AM EDT, Sep 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
argenx to Present at Upcoming Investor Conferences
Today 1:00 EDT
From
argenx SE
Via
GlobeNewswire
argenx Completes Acquisition of Forte Biosciences, Inc.
August 27, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
August 17, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 03, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
July 27, 2026
From
Forte Biosciences, Inc.
Via
Business Wire
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
July 16, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Host Autoimmune Myositis R&D Webinar
June 23, 2026
From
argenx SE
Via
GlobeNewswire
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
June 03, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
May 27, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 08, 2026
From
argenx SE
Via
GlobeNewswire
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 07, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2026 Health Care Conference
May 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026
From
argenx SE
Via
GlobeNewswire
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
April 18, 2026
From
argenx SE
Via
GlobeNewswire
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
March 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
February 19, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2026 Strategic Priorities
January 12, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Leadership Transition Marking Next Evolution of Growth
January 05, 2026
From
argenx SE
Via
GlobeNewswire
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
December 15, 2025
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
